Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Artemisia Absinthium→

Artemisia Absinthium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
84929-19-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Botanical herbal drugwormwood (Artemisia absinthium) bitter herb
Mechanism of action
Contains bitter sesquiterpene lactones and volatile oil constituents. Traditional use is based on bitter-taste stimulation of digestive secretions; no single defined molecular target is established.
Indications / reported uses
  • Traditional herbal use for temporary loss of appetite and mild dyspeptic complaints in adults in products meeting applicable herbal monograph requirements; not an authorised anti-parasitic treatment by default

Sources: EMA herbal monograph — Artemisia absinthium herba · EMA herbal medicinal products overview · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Artemisia Absinthium Environmental Risk Assessment (ERA) (the Artemisia Absinthium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.